GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nyxoah SA (CHIX:NYXHb) » Definitions » LT-Debt-to-Total-Asset

Nyxoah (CHIX:NYXHB) LT-Debt-to-Total-Asset : 0.10 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nyxoah LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Nyxoah's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.10.

Nyxoah's long-term debt to total assets ratio increased from Mar. 2023 (0.08) to Mar. 2024 (0.10). It may suggest that Nyxoah is progressively becoming more dependent on debt to grow their business.


Nyxoah LT-Debt-to-Total-Asset Historical Data

The historical data trend for Nyxoah's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyxoah LT-Debt-to-Total-Asset Chart

Nyxoah Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.52 0.09 0.06 0.07 0.09

Nyxoah Quarterly Data
Dec17 Dec18 Jun19 Dec19 Mar20 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 0.09 0.09 0.10

Nyxoah LT-Debt-to-Total-Asset Calculation

Nyxoah's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=11.489/124.157
=0.09

Nyxoah's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )/Total Assets (Q: Mar. 2024 )
=11.549/113.016
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nyxoah  (CHIX:NYXHb) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Nyxoah LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Nyxoah's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Nyxoah (CHIX:NYXHB) Business Description

Traded in Other Exchanges
Address
Rue Edouard Belin 12, Mont-Saint Guibert, BEL, 1435
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Nyxoah (CHIX:NYXHB) Headlines

No Headlines